Introduction: Psoriasis is a chronic inflammatory skin disease with systemic comorbidities as metabolic syndrome. Interleukin- 17(IL-17) has been identified as a central player in psoriasis associated inflammation.
Objective: To investigate serum IL-17 levels in relation to metabolic disturbances in psoriasis.
Materials and methods: Serum Il-17 levels were measured in 55 patients with psoriasis (26 having metabolic syndrome) and 50 healthy volunteers using the ELIZA method.
Results: Serum IL-17 levels were higher in psoriasis patients than controls (P=0.03), and in psoriatic patients with metabolic syndrome than psoriatic patients without metabolic syndrome (P=0.043). Serum IL-17 level was particularly increased in the presence of dyslipidemia and obesity (P=0.001 and 0.041 respectively).
Conclusion: Proinflammatory IL-17 in patients with psoriasis seems to be enhanced in the presence of metabolic syndrome particularly related to obesity and dyslipidemia.
Research Department
Research Journal
24th World Congress of Dermatology
Research Member
Research Publisher
NULL
Research Rank
3
Research Vol
NULL
Research Website
NULL
Research Year
2019
Research_Pages
NULL
Research Abstract